These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 19101796

  • 1. Levosimendan: from basic science to clinical practice.
    Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A.
    Heart Fail Rev; 2009 Dec; 14(4):265-75. PubMed ID: 19101796
    [Abstract] [Full Text] [Related]

  • 2. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y.
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [Abstract] [Full Text] [Related]

  • 3. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT.
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [Abstract] [Full Text] [Related]

  • 4. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M, Lehtonen L.
    Curr Pharm Des; 2005 Aug; 11(4):435-55. PubMed ID: 15725064
    [Abstract] [Full Text] [Related]

  • 5. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C.
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [Abstract] [Full Text] [Related]

  • 6. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L.
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [Abstract] [Full Text] [Related]

  • 7. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
    Ng TM.
    Pharmacotherapy; 2004 Oct; 24(10):1366-84. PubMed ID: 15628834
    [Abstract] [Full Text] [Related]

  • 8. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA, Wagstaff AJ.
    Drugs; 2003 Oct; 63(23):2651-71. PubMed ID: 14636085
    [Abstract] [Full Text] [Related]

  • 9. Levosimendan: a novel agent in heart failure.
    Koumallos N, Antoniades C, Tousoulis D, Shirodaria C, Stefanadis C.
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
    [Abstract] [Full Text] [Related]

  • 10. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F.
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [Abstract] [Full Text] [Related]

  • 11. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG, McGowan J.
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [Abstract] [Full Text] [Related]

  • 12. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikström G.
    Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
    [Abstract] [Full Text] [Related]

  • 13. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F.
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [Abstract] [Full Text] [Related]

  • 14. Effects of levosimendan on right ventricular function in patients with advanced heart failure.
    Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K, Nikolaou M, Filippatos G, Kremastinos D.
    Am J Cardiol; 2006 Dec 01; 98(11):1489-92. PubMed ID: 17126656
    [Abstract] [Full Text] [Related]

  • 15. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG, Nikitin N, McGowan J.
    Expert Rev Cardiovasc Ther; 2004 Jan 01; 2(1):9-19. PubMed ID: 15038409
    [Abstract] [Full Text] [Related]

  • 16. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
    Banfor PN, Preusser LC, Campbell TJ, Marsh KC, Polakowski JS, Reinhart GA, Cox BF, Fryer RM.
    Am J Physiol Heart Circ Physiol; 2008 Jan 01; 294(1):H238-48. PubMed ID: 17982006
    [Abstract] [Full Text] [Related]

  • 17. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S, Eha J, Heinpalu M, Lehtonen L, Loogna I, Mesikepp A, Planken U, Sandell EP.
    Eur J Clin Pharmacol; 1996 Jan 01; 49(6):451-8. PubMed ID: 8706769
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ, Domínguez Rodríguez A.
    Am J Cardiovasc Drugs; 2006 Jan 01; 6(2):69-75. PubMed ID: 16555860
    [Abstract] [Full Text] [Related]

  • 19. Levosimendan: a unique approach to the treatment of heart failure.
    Nawarskas JJ, Anderson JR.
    Heart Dis; 2002 Jan 01; 4(4):265-71. PubMed ID: 12147186
    [Abstract] [Full Text] [Related]

  • 20. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
    Antoniades C, Antonopoulos AS, Tousoulis D, Bakogiannis C, Stefanadi E, Stefanadis C.
    Curr Drug Metab; 2009 Feb 01; 10(2):95-103. PubMed ID: 19275545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.